CD274 and neoplasm: Overall, these results indicate that PD-1/PD-L1 inhibitors have limited single-agent efficacy in GCB lymphomas, but there remains significant clinical potential when combined with other therapies, including epigenetic modulators and agents targeting tumor metabolism, as discussed below.